PPARα mediates the hypolipidemic action of fibrates by antagonizing FoxO1

High-fructose consumption is associated with insulin resistance and diabetic dyslipidemia, but the underlying mechanism is unclear. We show in hamsters that high-fructose feeding stimulated forkhead box O1 (FoxO1) production and promoted its nuclear redistribution in liver, correlating with augmented apolipoprotein C-III (apoC-III) production and impaired triglyceride metabolism. High-fructose feeding upregulated peroxisome proliferator-activated receptor-γ coactivator-1β and sterol regulatory element binding protein-1c expression, accounting for increased fat infiltration in liver. High-fructose-fed hamsters developed hypertriglyceridemia, accompanied by hyperinsulinemia and glucose intolerance. These metabolic aberrations were reversible by fenofibrate, a commonly used anti-hypertriglyceridemia agent that is known to bind and activate peroxisome proliferator-activated receptor-α (PPARα). PPARα physically interacted with, but functionally antagonized, FoxO1 in hepatic apoC-III expression. These data underscore the importance of FoxO1 deregulation in the pathogenesis of hypertriglyceridemia in high-fructose-fed hamsters. Counterregulation of hepatic FoxO1 activity by PPARα constitutes an important mechanism by which fibrates act to curb apoC-III overproduction and ameliorate hypertriglyceridemia.

[1]  S. Iannello,et al.  Insulin resistance in obesity: metabolic mechanisms and measurement methods. , 1998, Molecular genetics and metabolism.

[2]  C. Ehnholm,et al.  Effect of serum and C‐apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase , 1976, FEBS letters.

[3]  G. Shulman,et al.  Targeting Foxo1 in Mice Using Antisense Oligonucleotide Improves Hepatic and Peripheral Insulin Action , 2006, Diabetes.

[4]  M. Baes,et al.  DNA Binding Preferences of PPARα/RXRα Heterodimers , 1997 .

[5]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[6]  M. Safar,et al.  Accumulation of Triglyceride-Rich Lipoprotein in Subjects With Abdominal Obesity: The Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 Study , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[7]  N. Shachter.  Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism , 2001, Current opinion in lipidology.

[8]  M. Baes,et al.  DNA binding preferences of PPAR alpha/RXR alpha heterodimers. , 1997, Biochemical and biophysical research communications.

[9]  C. Packard.  Overview of fenofibrate. , 1998, European heart journal.

[10]  永井 義夫.  Amelioration of high fructose-induced matabolic derangements by activation of PPARα , 2002 .

[11]  T. Leff,et al.  Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. , 1995, Journal of lipid research.

[12]  A. Minnich,et al.  A potent PPARα agonist stimulates mitochondrial fatty acid β-oxidation in liver and skeletal muscle , 2001 .

[13]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[14]  M. Lane,et al.  Convergence of peroxisome proliferator-activated receptor gamma and Foxo1 signaling pathways. , 2003, The Journal of biological chemistry.

[15]  H. Ginsberg,et al.  The Insulin Resistance Syndrome: Impact on Lipoprotein Metabolism and Atherothrombosis , 2000, Journal of cardiovascular risk.

[16]  M. Chapman.  Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. , 2003, Atherosclerosis.

[17]  J. Dallongeville,et al.  Cell Culture Conditions Determine Apolipoprotein CIII Secretion and Regulation by Fibrates in Human Hepatoma HepG2 Cells , 1999, Cellular Physiology and Biochemistry.

[18]  D. Accili,et al.  Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. , 2003, American journal of physiology. Endocrinology and metabolism.

[19]  A. Häkkinen,et al.  Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. , 2002, The Journal of clinical endocrinology and metabolism.

[20]  A. Scheen,et al.  PATHOPHYSIOLOGY OF TYPE 2 DIABETES , 2003, Acta clinica Belgica.

[21]  Christoph Handschin,et al.  Hyperlipidemic Effects of Dietary Saturated Fats Mediated through PGC-1β Coactivation of SREBP , 2005, Cell.

[22]  D. Befroy,et al.  Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease* , 2004, Journal of Biological Chemistry.

[23]  J. Auwerx,et al.  Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor α-deficient Mice* , 1997, The Journal of Biological Chemistry.

[24]  J. Altomonte,et al.  Basal insulin gene expression significantly improves conventional insulin therapy in type 1 diabetic rats. , 2002, Diabetes.

[25]  D. Accili,et al.  The forkhead transcription factor Foxo1 regulates adipocyte differentiation. , 2003, Developmental cell.

[26]  G. Lewis,et al.  Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster. , 2005, Endocrinology.

[27]  G. Marchesini,et al.  Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[28]  A. McCullough,et al.  Diabetes mellitus, obesity, and hepatic steatosis. , 2002, Seminars in gastrointestinal disease.

[29]  K. Adeli,et al.  Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia. , 2006, Atherosclerosis.

[30]  M. Cnop,et al.  The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. , 2003, Diabetes.

[31]  K. Maki.  Fibrates for treatment of the metabolic syndrome , 2004, Current atherosclerosis reports.

[32]  A. Minnich,et al.  A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. , 2001, American journal of physiology. Endocrinology and metabolism.

[33]  D. Accili,et al.  Transgenic rescue of insulin receptor-deficient mice. , 2004, The Journal of clinical investigation.

[34]  H. Maegawa,et al.  Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha. , 2002, American journal of physiology. Endocrinology and metabolism.

[35]  I. Salti,et al.  Management of dyslipidemia. , 2001, Le Journal medical libanais. The Lebanese medical journal.

[36]  G. Volpicelli,et al.  Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. , 1998, Molecular genetics and metabolism.

[37]  Peter Olson,et al.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0288 Minireview: Lipid Metabolism, Metabolic Diseases, and , 2022 .

[38]  P. Webb.  Faculty Opinions recommendation of Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. , 2005 .

[39]  J. Fruchart,et al.  Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. , 1992, Journal of lipid research.

[40]  C. S. Wang,et al.  Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. , 1985, The Journal of clinical investigation.

[41]  J. Altomonte,et al.  Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism. , 2006, Endocrinology.

[42]  G. Lewis,et al.  Ameliorated Hepatic Insulin Resistance Is Associated with Normalization of Microsomal Triglyceride Transfer Protein Expression and Reduction in Very Low Density Lipoprotein Assembly and Secretion in the Fructose-fed Hamster* , 2002, The Journal of Biological Chemistry.

[43]  Khosrow Adeli,et al.  Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. , 2002, Endocrine reviews.

[44]  S. Wright,et al.  Regulation of lipid metabolism and gene expression by fenofibrate in hamsters. , 2001, Biochimica et biophysica acta.

[45]  D. Accili,et al.  FoxOs at the Crossroads of Cellular Metabolism, Differentiation, and Transformation , 2004, Cell.

[46]  D. Accili,et al.  Regulation of insulin action and pancreatic β-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1 , 2002, Nature Genetics.

[47]  J. Auwerx,et al.  Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. , 1995, The Journal of clinical investigation.

[48]  P. Young,et al.  Induction of endogenous genes by peroxisome proliferator activated receptor alpha ligands in a human kidney cell line and in vivo , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[49]  K. Wassermann,et al.  Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists. , 2003, Journal of molecular endocrinology.

[50]  F. H. Man,et al.  The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding. , 2000, Atherosclerosis.

[51]  J. Xu,et al.  Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. , 2004, The Journal of clinical investigation.

[52]  D. Accili,et al.  Differential regulation of gene expression by insulin and IGF‐1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR , 2000, The EMBO journal.

[53]  A. Gotto.  Management of dyslipidemia. , 2002, The American journal of medicine.

[54]  K. Adeli,et al.  Mechanisms of metabolic dyslipidemia in insulin resistant states: deregulation of hepatic and intestinal lipoprotein secretion. , 2003, Frontiers in bioscience : a journal and virtual library.

[55]  K. Ogilvie,et al.  Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat. , 2001, Metabolism: clinical and experimental.

[56]  G. Watts,et al.  Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. , 2002, Clinical chemistry.

[57]  M. Hussain,et al.  Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly Published, JLR Papers in Press, September 16, 2002. DOI 10.1194/jlr.R200014-JLR200 , 2003, Journal of Lipid Research.

[58]  M. Lane,et al.  Convergence of Peroxisome Proliferator-activated Receptor γ and Foxo1 Signaling Pathways* , 2003, Journal of Biological Chemistry.

[59]  D. Accili,et al.  Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. , 2006, The Journal of clinical investigation.

[60]  C. Day.  Pathogenesis of steatohepatitis. , 2002, Best practice & research. Clinical gastroenterology.